Lori Brisbin is a molecular biologist who leads Texas Oncology’s Precision Medicine program. She is responsible for maximizing the use of precision medicine within Texas Oncology, focusing on data capture and utilization for research, as well as collaboration with pharmaceutical partners for clinical trials matching and data aggregation.
Ms. Brisbin previously served as chief commercial officer for Medfusion, where she led an expansion of the molecular oncology program and helped implement genetic test data capture capabilities for Texas Oncology and Rocky Mountain Cancer Centers. She previously worked at Roche Molecular Systems, QIAGEN, and Novartis, where she helped develop molecular genetic solutions for oncology and infectious disease.
Lori Brisbin earned a Master of Science degree in molecular biology from Syracuse University in Syracuse, New York.